Atterocor Raises $16M in Series A Funding

Atterocor, Inc., an Ann Arbor, Michigan-based developer of an innovative therapy for adrenal cancer, has raised $16m in Series A venture capital funding.

The round was led by Frazier Healthcare and 5AM Ventures.

The company intends to use the funding to accelerate development of its lead program to the clinic.

Founded in 2012 by Julia Owens, Ph.D., President and CEO, Raili Kerppola, Ph.D., MBA, COO, and Gary Hammer, M.D., Ph.D., scientific advisor, Atterocor is a drug development company focused on novel therapies for adrenal cancer, which is often diagnosed in the late stages of disease when there is a very poor patient prognosis. This form of cancer is rare with approximately 600 patients diagnosed in the U.S. each year.



Join the discussion